U.S. Microstrategy, Snowflake, Target
Corrects company name to Aclaris Therapeutics in table entry for Cantor Fitzgerald's research action
Nov 21 (Reuters) -Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Microstrategy, Snowflake, and Target, on Thursday.
HIGHLIGHTS
* Dycom Industries Inc DY.N: D.A. Davidson raises target price to $220 from $210 |
* Microstrategy Inc MSTR.O: BTIG raises target price to $570 from $290 |
* Snowflake Inc SNOW.N: Piper Sandler raises target price to $185 from $165 |
* Target Corp TGT.N: Jefferies cuts target price to $165 from $195 |
* Williams-Sonoma Inc WSM.N: Jefferies raises target price to $194 from $156 |
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order.
* Aclaris Therapeutics Inc ACRS.O: Cantor Fitzgerald raises to overweight from neutral |
* Argenx SE ARGX.O: Raymond James raises target price to $770 from $688 |
* Bellring Brands Inc BRBR.N: Jefferies raises target price to $86 from $84 |
* Berry Global Group Inc BERY.N: RBC raises target price to $73 from $69 |
* Danimer Scientific Inc DNMR.N: TD Cowen cuts target price to $5.5 from $40 |
* Doximity Inc DOCS.N: JP Morgan raises target price to $48 from $30 |
* Dycom Industries Inc DY.N: D.A. Davidson raises target price to $220 from $210 |
* Farmers National Banc FMNB.O: Piper Sandler assumes coverage with neutral rating; PT $17 |
* Gitlab Inc GTLB.O: TD Cowen raises target price to $70 from $63 |
* Gulfport Energy Corp GPOR.N: Gerdes Energy Research cuts to neutral from buy |
* Jack In the Box Inc JACK.O: Jefferies cuts target price to $46 from $50 |
* Jack In the Box Inc JACK.O: RBC cuts target price to $65 from $70 |
* Jacobs Solutions Inc J.N: RBC cuts target price to $152 from $167 |
* Lemonade Inc LMND.N: Piper Sandler raises target price to $44 from $25 |
* Liberty Media Corp FWONK.O: JP Morgan raises target price to $96 from $95 |
* Madrigal Pharmaceuticals Inc MDGL.O: Oppenheimer raises PT to $400 from $350 |
* Microstrategy Inc MSTR.O: BTIG raises target price to $570 from $290 |
* Newamsterdam pharma Company NV NAMS.O: Leerink Partners raises PT to $45 from $42 |
* News Corp NWSA.O: JP Morgan raises target price to $40 from $37 |
* Nio Inc NIO.N: JP Morgan cuts target price to $7 from $8 |
* Nvidia Corp NVDA.O: Bernstein raises target price to $175 from $155 |
* Nvidia Corp NVDA.O: HSBC cuts target price to $195 from $200 |
* Nvidia Corp NVDA.O: JP Morgan raises target price to $170 from $155 |
* Nvidia Corp NVDA.O: TD Cowen raises target price to $175 from $165 |
* Palo Alto Networks Inc PANW.O: BTIG raises target price to $414 from $395 |
* Palo Alto Networks Inc PANW.O: D.A. Davidson raises PT to $435 from $415 |
* Palo Alto Networks Inc PANW.O: Piper Sandler raises PT to $385 from $330 |
* Pyxis Oncology Inc PYXS.O: RBC raises target price to $10 from $7 |
* Resideo Technologies Inc REZI.N: JP Morgan raises target price to $31 from $27 |
* Sage Therapeutics Inc SAGE.O: RBC raises to sector perform from underperform |
* Sage Therapeutics Inc SAGE.O: TD Cowen cuts target price to $9 from $10 |
* Salesforce Inc CRM.N: TD Cowen raises target price to $340 from $290 |
* Snowflake Inc SNOW.N: Barclays raises target price to $172 from $142 |
* Snowflake Inc SNOW.N: D.A. Davidson raises target price to $200 from $175 |
* Snowflake Inc SNOW.N: Jefferies raises target price to $180 from $145 |
* Snowflake Inc SNOW.N: JP Morgan raises target price to $185 from $175 |
* Snowflake Inc SNOW.N: Piper Sandler raises target price to $185 from $165 |
* Snowflake Inc SNOW.N: RBC raises target price to $188 from $175 |
* Sotera Health Co SHC.O: JP Morgan cuts target price to $13 from $15 |
* Syndax Pharmaceuticals Inc SNDX.O: JP Morgan raises PT to $38 from $33 |
* Target Corp TGT.N: D.A. Davidson cuts target price to $150 from $190 |
* Target Corp TGT.N: Jefferies cuts target price to $165 from $195 |
* Target Corp TGT.N: JP Morgan cuts target price to $139 from $167 |
* Target Corp TGT.N: Oppenheimer cuts target price to $165 from $185 |
* Target Corp TGT.N: Piper Sandler cuts target price to $130 from $156 |
* Target Corp TGT.N: Roth MKM cuts target price to $131 from $157 |
* Target Corp TGT.N: TD Cowen cuts target price to $145 from $165 |
* Target Corp TGT.N: Telsey Advisory Group cuts target price to $150 from $195 |
* TJX Companies Inc TJX.N: Goldman Sachs raises target price to $137 from $133 |
* TPI Composites Inc TPIC.O: Jefferies cuts target price to $2.3 from $4.3 |
* Ultragenyx Pharmaceutical Inc RARE.O: JP Morgan cuts PT to $102 from $105 |
* Williams-Sonoma Inc WSM.N: Jefferies raises target price to $194 from $156 |
* Williams-Sonoma Inc WSM.N: JP Morgan raises target price to $153 from $145 |
* Williams-Sonoma Inc WSM.N: RBC raises target price to $189 from $162 |
(Compiled by Bengaluru Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
